Under obese conditions, hepatic MDM2 overexpression leads to proteasomal degradation of ApoB, thereby lowering TG‐VLDL output, resulting in hepatic steatosis, oxidative stress, and inflammation. Here, MDM2 is linked to fatty liver disease.